Intrauterine Devices Market Size & Share 2025 - 2034

Intrauterine Devices Market Size

According to a recent study by Global Market Insights Inc., the global intrauterine devices (IUDs) market was valued at USD 4 billion in 2024. The market is expected to grow from USD 4.3 billion in 2025 to USD 11 billion in 2034, at a CAGR of 10.9% during the forecast period,

The high market growth is attributed to the favorable regulatory scenario, rising awareness among women regarding various IUD applications, and a high number of unintended pregnancies, among others.
 

IUDs are vital contraceptives, offering a highly effective, long-term, and reversible solution for birth control. Key players of the industry are AbbVie, CooperSurgical, Contrel Europe, and Bayer, among others. These devices are valued for their minimal maintenance, convenience, and ability to provide protection for up to 10 years, depending on the type.
 

The market has increased from USD 3.3 billion in 2021 and reached USD 3.8 billion in 2023, with a historic growth rate of 6.7%. This growth was primarily driven by the rising demand for long-term, reversible contraceptive solutions, increased awareness about family planning, and supportive government initiatives across both developed and emerging economies.
 

IUDs are now increasingly recognized for their broader health benefits, including the management of heavy menstrual bleeding, endometriosis, and even perimenopausal symptoms. Educational campaigns, digital health platforms, and improved access to reproductive health information have empowered women to make informed choices about long-term birth control options. This shift in perception is encouraging more women to consider IUDs not just for pregnancy prevention, but as a proactive tool for overall reproductive health management. Additionally, the growing involvement of healthcare providers in counseling women about the safety, efficacy, and non-contraceptive benefits of IUDs has further fueled adoption.
 

Intrauterine devices (IUDs) are small, flexible, T-shaped contraceptive tools placed inside the uterus to prevent pregnancy. Designed for long-term use, they offer a reversible and highly effective method of birth control.
 

Intrauterine Devices Market Trends

The intrauterine devices industry is experiencing rapid growth, driven by innovations in device design, materials, and insertion techniques.
 

• For instance, the use of shape memory alloys in newer IUDs helps prevent malposition and uterine wall perforation, enhancing both user experience and clinical outcomes. Additionally, the development of smaller, low-dose, and hormone-free IUDs with up to 99% efficacy over three years is expanding the market by addressing concerns related to traditional devices.
   
• Furthermore, advancements include ergonomic applicators and pre-loaded insertion kits, which simplify the insertion process and reduce discomfort, making IUDs more accessible to a broader demographic. Research is also underway for smart IUDs capable of monitoring hormone levels and uterine conditions, offering personalized reproductive health insights. These innovations not only improve patient satisfaction but also support the growing demand for long-acting reversible contraception (LARC).
   
• Moreover, new materials like iron-based IUDs are being explored to offer non-hormonal alternatives with fewer side effects, catering to women seeking hormone-free options. Thus, these technological advancements are reshaping the IUD industry and fueling sustained market expansion.
   

Intrauterine Devices Market Analysis

The global market for intrauterine devices was valued at USD 3.3 billion in 2021. The market size reached USD 3.8 billion in 2023, from USD 3.6 billion in 2022.
 

Based on the product, the market is segmented into copper IUD and hormonal IUD. The hormonal IUD segment accounted for 53.8% of the market in 2024 due to its dual benefits of long-term contraception and menstrual health management, high efficacy, low maintenance, and growing awareness among women and healthcare providers. The segment is expected to exceed USD 6.1 billion by 2034, growing at a CAGR of 11.2% during the forecast period.
 

On the other hand, the copper IUD segment held a market share of 46.2% in 2024. The growth of this segment can be attributed to its long-term effectiveness, hormone-free nature, affordability, and increasing consumer preference for non-hormonal contraceptive options.
 

• This dominance of hormonal IUDs in the market is driven by their high efficacy, long-acting protection, and additional health benefits such as reduced menstrual bleeding and relief from symptoms of endometriosis. Hormonal IUDs, particularly those releasing levonorgestrel, are favored by healthcare providers and patients alike for their dual role in contraception and menstrual health management.
   
• The popularity of hormonal IUDs is further supported by ongoing product innovations, such as slimmer designs for easier insertion and improved comfort, and regulatory approvals from agencies like the FDA and EMA. These devices offer 3 to 5 years of protection, making them ideal for women seeking low-maintenance, reversible birth control.
   

Based on age group, the intrauterine devices market is segmented into 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, and 45+. The 30-34 segment dominated the market in 2024, accounting for USD 1.1 billion, and is anticipated to grow at a CAGR of 11.1% during the forecast period.
 

• The 15-19 segment held a revenue of USD 268.1 million in 2024, with projections indicating a steady expansion at 9.9% CAGR from 2025 to 2034.
   
• The 20-24 segment was valued at USD 550 million in 2024.
   
• The 25-29 segment held a revenue of USD 934.9 million in 2024, with projections indicating a steady expansion at 11.4% CAGR from 2025 to 2034.
   
• The 35-39 segment is expected to grow with a CAGR of 10.9%.
   
• The 40-44 segment held a market share of 10.5% in 2024.
   
• The 45+ segment was valued at USD 210.6 million in 2024.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the intrauterine devices market is classified into hospitals, gynecology clinics, and community health care centers. The hospitals segment dominated the market with a revenue share of 53.2% in 2024 and is expected to reach USD 5.8 billion within the forecast period.
 

• Hospitals across the globe play a central role in delivering long-acting reversible contraception (LARC), including IUDs. Their importance is amplified by the availability of skilled gynecologists and obstetricians who ensure safe and effective insertion procedures. In many countries, hospitals are increasingly adopting protocols for immediate postpartum IUD insertion, which not only enhances access but also contributes to reducing unintended pregnancies. This trend is particularly evident in regions with strong maternal health programs and integrated reproductive care services.
   
• Gynecology clinics are witnessing steady growth worldwide, driven by rising demand for specialized reproductive care and personalized contraceptive counseling. With advanced IUD insertion technologies and growing awareness of long-term contraceptive options, these clinics are becoming preferred access points, especially in urban and semi-urban areas.
   
• The community health care centers segment was valued at USD 354.4 million in 2024, driven by increasing access to affordable reproductive health services and growing adoption of IUDs in underserved and rural populations.
   

North America Intrauterine Devices Market
 

North America dominated the global intrauterine devices industry with the revenue share of 37.3% in 2024.
 

• The U.S. market was valued at USD 1.21 billion and USD 1.30 billion in 2021 and 2022, respectively. The market size reached USD 1.44 billion in 2024, growing from USD 1.36 billion in 2023, and is anticipated to grow at a CAGR of 10.3% between 2025 and 2034.
   
• The region reports high rates of unintended pregnancies, with approximately 45% of all pregnancies in the U.S. being unplanned in 2022, according to the CDC. Healthcare providers recommend IUDs to minimize the risks of unplanned pregnancies.
   
• The U.S. Department of Health and Human Services reported that insurance coverage for IUDs increased from 87% in 2021 to 92% in 2023 under the Affordable Care Act. Government family planning initiatives allocated USD 286.5 million in Title X funding for 2024, supporting the growing demand for IUDs.
   
• Furthermore, the growing public health efforts and awareness programs have advocated the use of IUDs as a safe, effective and easy way to prevent pregnancy. The higher preference for long-acting reversible contraception (LARCs) due to longer duration and less compliance compared to daily pills or short-term methods has furthered IUD use among varying age groups in the U.S. and Canada.
  
   

Europe Intrauterine Devices Market
 

European market for intrauterine devices accounted for USD 727.5 million in 2024.
 

• In Europe, health care systems and family planning allow access to reproductive medicine. For instance, in 2023, 65% of the cost of an IUD was covered by France's national health insurance, and in the UK, free IUD service was offered to nearly 150,000 women via the NHS.
   
• Germany's public health insurance system reported a 28% increase in IUD coverage between 2021 and 2023. Spain's Ministry of Health data shows that government-subsidized IUD programs reached 85,000 women in 2022, representing a 15% increase from 2021. These supportive healthcare policies continue to drive IUD adoption across various demographic segments.
   
• Europe continues to witness unplanned pregnancies, particularly among younger women and migrant populations. IUDs play a crucial role in reducing these cases due to their long-term effectiveness. Public health campaigns and awareness initiatives by NGOs and healthcare systems amplify their adoption.
  
   

Asia Pacific Intrauterine Devices Market
 

The Asia Pacific market is anticipated to grow at a CAGR of 11.5% during 2025 to 2034.
 

• Many Asia Pacific countries, such as India and China, have policies aimed at population control and family planning that encourage the use of IUDs. IUDs are made widely accessible for many people of low and middle income due to subsidized and free access through the public healthcare system. Such intensive government action results in considerable market penetration.
   
• Rapid improvements in healthcare delivery systems, especially in countries like India, China, and Southeast Asia, are increasing access to gynecological services. The growing presence of women’s health clinics, hospitals, and community health programs is making IUD insertion and follow-up services more widely available. This accessibility supports higher adoption rates.
   
• Further, regional manufacturers and multinational corporations are also expanding their activities in the Asia Pacific region through the use of low-priced targeted products. The availability of low-priced copper IUDs and highly priced hormonal IUDs ensures that people of different income levels have access.
  
   

Latin America Intrauterine Devices Market
 

The Latin America market is expected to experience robust growth over 2025 to 2034.
 

• The Latin America market is mostly motivated by the government-supported family planning programs and public health policies that promote long-acting reversible contraceptives (LARCs) as a reasonable and advantageous method. Brazil, Mexico, and Argentina are examples of countries that have incorporated IUDs into their national health systems and subsidized their provision, at little or no charge, to women of diverse socioeconomic statuses.
   
• Additionally, the convenience and low maintenance of IUDs make them attractive compared to daily oral contraceptives or short-term methods. Urbanization, greater female workforce participation, and cultural shifts toward modern contraceptives are also supporting the market’s expansion. Thus, these factors are creating favorable conditions for the steady growth of the IUD market in Latin America.
   
• Countries such as Brazil, Mexico, and Argentina have integrated IUDs into national healthcare systems, often providing them at low or no cost to women across various socioeconomic backgrounds.
  
   

Middle East and Africa Intrauterine Devices Market
 

The Middle East and Africa (MEA) market is expected to experience robust growth over the analysis timeframe.
 

• In the MEA region, the growing demand for family planning in the areas of high fertility and population growth continues to drive market demand. International and government organizations, including the United Nations (UN) and World Health Organization (WHO), sponsor reproductive health programs promoting the use of long-acting, reversible contraceptives (LARCs) such as IUDs.
   
• Additionally, the inclusion of family planning in primary health care services, as well as subsidized health care systems, is improving contraceptive choice, especially in developing countries. Moreover, in urban areas, the changing societal attitudes towards women joining the labour market and the increasing awareness of modern contraceptive practices have, to some extent, contributed to the growing use of IUDs.
   
• Similarly, the market is supported by the expansion of healthcare infrastructure and increased availability of gynecological services in both public and private sectors. Multinational companies and regional players are introducing affordable copper IUDs and advanced hormonal devices to cater to different income groups, thereby widening consumer choice.
   
• Non-governmental organizations and community-based health programs play a crucial role in bridging access gaps, especially in rural and underserved areas. While cultural and religious barriers still limit widespread adoption in certain parts of the Middle East, education campaigns and government-backed initiatives are slowly reshaping perceptions, creating long-term growth opportunities for IUD adoption across the MEA region.
   

Intrauterine Devices Market Share

Leading industry players such as AbbVie, Bayer, DKT, PREGNA, and CooperSurgical hold around 39% of the market share in the competitive intrauterine devices industry. These companies maintain their leading position by combining strong product lines, business collaborations with healthcare providers, regulatory clearances, and consistent product innovation.
 

Major companies in the intrauterine devices market are reinforcing their competitive positions by focusing on innovation, including the development of frameless and biodegradable IUDs, user-friendly insertion systems, and hormone-free alternatives like copper-based spherical designs. Bayer AG continues to lead with its robust hormonal IUD portfolio, including the widely used Mirena and Kyleena systems. The company recently received FDA approval for an extended-duration Mirena IUD, now offering up to 8 years of protection.
 

Similarly, CooperSurgical is advancing its position through its hormone-free IUD, Paragard, which provides up to 10 years of contraception. The company has launched consumer engagement initiatives and digital tools to improve patient education and access. Its focus on hormone-free solutions appeals to a growing segment of women seeking non-hormonal options.
 

Meanwhile, other key players, such as AbbVie, DKT, PREGNA, and Sebela Pharmaceuticals, are investing in next-generation IUDs with customizable hormone release, longer duration, and improved biocompatibility. These companies are also exploring biodegradable materials and frameless designs to enhance comfort and reduce side effects.
 

Intrauterine Devices Market Companies

A few of the prominent players operating in the intrauterine devices industry include:

• AbbVie
• Bayer
• CooperSurgical
• DKT
• eurogine
• GIMA
• GYNO CARE
• HLL Lifecare Limited
• Medicines360
• Meril
• MONA LISA
• PREGNA
• Prosan
• Sebela Pharmaceuticals
• SMB

• AbbVie

AbbVie has made significant strides in democratizing access to hormonal IUDs with Liletta, a cost-effective levonorgestrel-releasing system. Designed for up to 8 years of use, Liletta is FDA-approved and widely adopted in public health clinics across the globe. AbbVie’s strategy emphasizes affordability, clinical efficacy, and broad accessibility, particularly for underserved populations.
 

• Bayer

Bayer leads the intrauterine devices market with a share of 18% in 2024. Bayer leads the IUD market with its flagship hormonal IUDs, which are known for their long duration, high efficacy, and additional therapeutic benefits such as reduced menstrual bleeding. Bayer’s commitment to innovation, sustainability, and expanded access is reflected in its efforts to improve device design and broaden contraceptive availability.
 

• CooperSurgical

CooperSurgical distinguishes itself with Paragard, an FDA-approved, hormone-free copper IUD, offering up to 10 years of protection. The company is investing in consumer engagement platforms and digital education tools to raise awareness about non-hormonal options. CooperSurgical’s focus on reusability, patient comfort, and sustainability aligns with the growing demand for personalized and eco-conscious contraceptive solutions.
 

Intrauterine Devices Industry News:

• In February 2025, Sebela Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted approval of MIUDELLA for the prevention of pregnancy in females of reproductive potential for up to three years. This approval may expand the company’s product range and help generate enhanced business revenue.
   
• In November 2023, Bayer and CrossBay Medical Inc. announced a collaboration and licensing agreement to develop and produce a single-handed inserter integrated with Bayer’s leading hormonal intrauterine system (IUS) portfolio. This strategic move has strengthened Bayer’s product offerings and enhanced its competitiveness in the IUD market by improving ease of use for healthcare providers and comfort for patients.
   

The intrauterine devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Copper IUD
• Hormonal IUD

Market, By Age Group

• 15-19
• 20-24
• 25-29
• 30-34
• 35-39
• 40-44
• 45+

Market, By End Use

• Hospitals
• Gynecology clinics
• Community health care centers

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE